These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23701117)

  • 1. A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
    Vojvodic M; Hansford LM; Morozova O; Blakely KM; Taylor P; Fathers KE; Moffat J; Marra M; Smith KM; Moran MF; Kaplan DR
    Curr Drug Discov Technol; 2013 Dec; 10(4):283-304. PubMed ID: 23701117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
    Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
    Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
    Dai Y; Chen S; Shah R; Pei XY; Wang L; Almenara JA; Kramer LB; Dent P; Grant S
    Blood; 2011 Feb; 117(6):1947-57. PubMed ID: 21148814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
    Tarpley M; Abdissa TT; Johnson GL; Scott JE
    Anticancer Res; 2014 Apr; 34(4):1629-35. PubMed ID: 24692691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
    Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
    Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
    Ozanne J; Prescott AR; Clark K
    Biochem J; 2015 Jan; 465(2):271-9. PubMed ID: 25351958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C
    Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
    Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
    Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
    Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
    Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src as a Therapeutic Target in Biliary Tract Cancer.
    Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
    Buettner R; Mesa T; Vultur A; Lee F; Jove R
    Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
    Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
    Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
    Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
    Ke J; Chelvarajan RL; Sindhava V; Robertson DA; Lekakis L; Jennings CD; Bondada S
    Mol Cancer; 2009 Dec; 8():132. PubMed ID: 20043832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.